<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-α is produced in brain in response to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, and promotes neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Biologic TNF inhibitors (TNFIs), such as the etanercept, cannot be developed as new <z:hpo ids='HP_0001297'>stroke</z:hpo> treatments because these large molecule drugs do not cross the blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>A <z:chebi fb="2" ids="33602">BBB</z:chebi>-penetrating biologic TNFI was engineered by fusion of the type II human TNF receptor (TNFR) to each heavy chain of a genetically engineered chimeric monoclonal antibody (MAb) against the mouse transferrin receptor (TfR), designated as cTfRMAb-TNFR fusion protein </plain></SENT>
<SENT sid="3" pm="."><plain>The cTfRMAb domain of the fusion protein acts as a molecular Trojan horse to deliver the fused TNFR across the <z:chebi fb="2" ids="33602">BBB</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Etanercept or the cTfRMAb-TNFR fusion protein (1 mg/kg) was administered intravenously in adult mice subjected to 1-hour reversible middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> up to 90 minutes after the occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>Neuroprotection was assessed at 24 hours or 7 days after occlusion </plain></SENT>
<SENT sid="6" pm="."><plain>The cTfRMAb-TNFR fusion protein treatment caused a significant 45%, 48%, 42%, and 54% reduction in hemispheric, cortical, and subcortical <z:hpo ids='HP_0001297'>stroke</z:hpo> volumes, and neural deficit, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Intravenous etanercept had no therapeutic effect </plain></SENT>
<SENT sid="8" pm="."><plain>Biologic TNFIs can be reengineered for <z:chebi fb="2" ids="33602">BBB</z:chebi> penetration, and the IgG-TNFR fusion protein is therapeutic after delayed intravenous administration in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>